A Phase 1 Study to Assess the Safety and Tolerability of VGR-R01 in Patients With Bietti Crystalline Dystrophy
Latest Information Update: 24 Jan 2023
At a glance
- Drugs VGR-R01 (Primary)
- Indications Bietti crystalline dystrophy
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shanghai Vitalgen BioPharma
Most Recent Events
- 24 Jan 2023 New trial record